Literature DB >> 11442644

Barriers to compliance with prophylaxis therapy in haemophilia.

M R Hacker1, S Geraghty, M Manco-Johnson.   

Abstract

Prophylaxis, or the practice of routine replacement infusions of clotting factor concentrate in persons with severe haemophilia, is a demanding medical regimen. Prophylactic infusions require direct venepuncture or sterile entry into a central venous access device on a regular basis. A telephone survey was conducted to elicit information regarding the barriers to compliance with prophylaxis. The Mountain States Regional Haemophilia and Thrombosis Center has recommended prophylaxis to 52 male patients with haemophilia A or B. The haemophilia nurse attempted to contact all of these patients or their parents, and contact was made with 38 (73.1%) of them. Respondents were asked about the following issues: their decision to initiate prophylaxis; their self-rated compliance; the challenges, barriers, and facilitators of prophylaxis; and their perceived value of the therapy. Four patients (10.5%) elected not to begin prophylaxis. Of the 34 persons who began prophylaxis, 20 respondents (58.8%) rated their compliance as excellent. Nearly one-third of the families with excellent compliance (giving 75-100% of prescribed infusions) stated that the time-consuming nature of prophylaxis was the most significant challenge of the regimen. In addition, 58.3% of the families that gave less than the prescribed number of infusions reported that the time commitment was the primary reason for missing infusions. Knowledge of the benefits of prophylaxis was the primary facilitator of compliance for 44.1% of families. Ninety-seven percent of respondents rated prophylaxis as very valuable. These data show that despite the known benefits of prophylaxis, it is a demanding medical regimen, and compliance is imperfect. In addition, this study underscores the importance of providing continuing support and education for patients and families who are implementing prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442644     DOI: 10.1046/j.1365-2516.2001.00534.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  56 in total

Review 1.  Practical aspects of extended half-life products for the treatment of haemophilia.

Authors:  Thierry Lambert; Gary Benson; Gerry Dolan; Cedric Hermans; Victor Jiménez-Yuste; Rolf Ljung; Massimo Morfini; Silva Zupančić-Šalek; Elena Santagostino
Journal:  Ther Adv Hematol       Date:  2018-09-06

2.  BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice.

Authors:  Ekta Seth Chhabra; Tongyao Liu; John Kulman; Susannah Patarroyo-White; Buyue Yang; Qi Lu; Douglas Drager; Nancy Moore; Jiayun Liu; Amy M Holthaus; Jurg M Sommer; Ayman Ismail; Deana Rabinovich; Zhan Liu; Arjan van der Flier; Allison Goodman; Chris Furcht; Mark Tie; Tyler Carlage; Randy Mauldin; Terrence M Dobrowsky; Zhiqian Liu; Oblaise Mercury; Lily Zhu; Baisong Mei; Volker Schellenberger; Haiyan Jiang; Glenn F Pierce; Joe Salas; Robert Peters
Journal:  Blood       Date:  2020-04-23       Impact factor: 22.113

3.  Clotting factors: Stretching time.

Authors:  Neil Savage
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

4.  Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

Authors:  Amy D Shapiro; Pantep Angchaisuksiri; Jan Astermark; Gary Benson; Giancarlo Castaman; Pratima Chowdary; Hermann Eichler; Victor Jiménez-Yuste; Kaan Kavakli; Tadashi Matsushita; Lone Hvitfeldt Poulsen; Allison P Wheeler; Guy Young; Silva Zupancic-Salek; Johannes Oldenburg
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

5.  Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study.

Authors:  Ezio Zanon; Annarita Tagliaferri; Samantha Pasca; Cosimo P Ettorre; Lucia D Notarangelo; Chiara Biasioli; Anna B Aru; Marta Milan; Silvia Linari; Angiola Rocino; Fabio Gagliano; Giovanni Di Minno; Gabriella Gamba; Rita C Santoro; Piercarla Schinco; Marco Marietta; Axel Seuser; Sylvia von Mackensen
Journal:  Blood Transfus       Date:  2019-06-05       Impact factor: 3.443

6.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

7.  Infected tooth extraction, bone grafting, immediate implant placement and immediate temporary crown insertion in a patient with severe type-B hemophilia.

Authors:  Jose Luis Calvo-Guirado; Georgios E Romanos; Rafael Arcesio Delgado-Ruiz
Journal:  BMJ Case Rep       Date:  2019-03-22

8.  Design and Usability of an Electronic Health Record-Integrated, Point-of-Care, Clinical Decision Support Tool for Modeling and Simulation of Antihemophilic Factors.

Authors:  Susan M Abdel-Rahman; Harpreet Gill; Shannon L Carpenter; Pathe Gueye; Brian Wicklund; Matt Breitkreutz; Arindam Ghosh; Avinash Kollu
Journal:  Appl Clin Inform       Date:  2020-04-08       Impact factor: 2.342

Review 9.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

Review 10.  BAY 81-8973, a full-length recombinant factor VIII for the treatment of hemophilia A: product review.

Authors:  Johnny N Mahlangu; Sanjay P Ahuja; Jerzy Windyga; Nikki Church; Anita Shah; Lawrence Schwartz
Journal:  Ther Adv Hematol       Date:  2018-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.